Latest News about Biotech
Recent news which mentions Biotech
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
November 04, 2024
From Benzinga
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
November 01, 2024
From Benzinga
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
November 01, 2024
From Benzinga
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
November 01, 2024
From Benzinga
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
November 01, 2024
Tickers
ARGX
From Benzinga
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
November 01, 2024
From Benzinga
From Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
November 01, 2024
From Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
From Benzinga
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
October 31, 2024
From Benzinga
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
October 30, 2024
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
From Benzinga
From Benzinga
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
October 30, 2024
From Benzinga
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
October 30, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.